Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide

European Journal of Gynaecological Oncology

Volumn 35, Issue 1, 2014, Pages 59-61

  Karimi Zarchi, M ^a   Forat Yazdi, M ^a   Vafaeenasab, M R ^a   Nakhaie Moghadam, M ^a   Miratashi Yazdi, A ^a   Teimoori, S ^a   Dehghani Tafti, A ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Chemotherapy; Cyclophosphamide; Fertility; Menstrual reverse

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; TRIPTORELIN;

ADULT; ARTICLE; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; MIDDLE AGED; OLIGOMENORRHEA; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; ESTRADIOL; FEMALE; FERTILITY PRESERVATION; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; MIDDLE AGED; ORGAN SPARING TREATMENTS; TRIPTORELIN PAMOATE;

EID: 84895814973     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: 10.12892/ejgo23352014     Document Type: Article

References (11)

1. Dunn L., Fox K.R.: "Techniques for fertility preservation in patients with breast cancer". Curr. Opin. Obstet. Gynecol., 2009, 21, 68.
2. Sverrisdottir A., Nystedt M., Johansson H., Fomander T.: "Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer". Breast Cancer Res. Treat., 2009, 117, 561.
3. Barooti E., Sadeghi N., Karimi-Zarchi M., Soltani H.R.: "New results regarding trends in Iranian women's health and a comparison with WHO". Clin. Exp. Obstet. Gynecol., 2011, 38, 390.
4. Anderson W.F., Chuk C., Devesa S.S.: "Distinct incidence patterns among insitu and invasive breast cancer carcinomas with possible etiologic implication". Breast Cancer Res. Treat., 2004, 88, 149.
5. Badawy A., Elnashar A., El-Ashry M., Shahat M.: "Gonadotropin- releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study". Fertil. Steril., 2009, 91, 694.
6. Del Mastro L., Catzeddu T., Boni L., Bell C., Sertoli M.R., Bighin C., et al.: "Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients". Ann. Oncol., 2006, 17, 74.
7. Tan O., Bukulmez O.: "Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists". Curr. Opin. Obstet. Gynecol., 2011, 23, 238.
8. Clowse M.E., Behera M.A., Anders C.K., Copland S., Coffman C.J., Leppert P.C., Bastian L.A.: "Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis". J. Womens Health (Larchmt), 2009, 18, 311.
9. Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., Haim N.: "Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy". Hum. Reprod., 1996, 11, 1620.
10. Blumenfeld Z., Dann E., Avivi I., Epelbaum R., Rowe J.M.: "Fertility after treatment for Hodgkin's disease". Ann. Oncol., 2002, 13, 138.
11. Blumenfeld Z., Avivi I., Eckman A., Epelbaum R., Rowe J.M., Dann E.J.: "Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma". Fertil. Steril., 2008, 89, 166.